P10636

※ Protein Information

Tag	Content
UniProt Accession	TAU_HUMAN; P10636;
Entrez ID	4137
GenBank Protein ID	NM_001123066.3; NM_001123067.3; NM_001203252.1; NM_005910.5; NM_016834.4; NM_016835.4; NM_016841.4;
GenBank Nucleotide ID	NP_001116538.2; NP_001116539.1; NP_001190181.1; NP_005901.2; NP_058518.1; NP_058519.3; NP_058525.1;
Protein Name	Microtubule-associated protein tau (Neurofibrillary tangle protein) (Paired helical filament-tau) (PHF-tau)
Gene Name	MAPT; MAPTL; MTBT1; TAU
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Functional Description Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
Sequence (Fasta)	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG 60 SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG 120 HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG 180 GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA 240 QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE 300 FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEGPEARGP SLGEDTKEAD LPEPSEKQPA 360 AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKHPTPGSS 420 DPLIQPSSPA VCPEPPSSPK YVSSVTSRTG SSGAKEMKLK GADGKTKIAT PRGAAPPGQK 480 GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP 540 KKVAVVRTPP KSPSSAKSRL QTAPVPMPDL KNVKSKIGST ENLKHQPGGG KVQIINKKLD 600 LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHKPG GGQVEVKSEK 660 LDFKDRVQSK IGSLDNITHV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVSGDT 720 SPRHLSNVSS TGSIDMVDSP QLATLADEVS ASLAKQGL 759 Fasta Sequence >P10636\|MAPT; MAPTL; MTBT1; TAU\|Homo sapiens (Human) MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Methylation	Alzheimer's disease		D		23943618; 3779734
1	[Reference]: We propose that alterations in the membrane localization of PP2A and Tau following down-regulation of LCMT1 may lead to PP2A and Tau dysfunction in AD.
2	Phosphorylation	Alzheimer's disease		P		23638980
2	[Reference]: ecovery is 90% for a pure phosphopeptide.
3	Glycosylation	Alzheimer's disease		P		24279329
3	[Reference]: The major pathological hallmarks in AD are neurofibrillary tangles and amyloid plaques. Neurofibrillary tangles are composed of phosphorylated tau, and the plaques are composed of amyloid -peptide (A), which is generated from amyloid precursor?protein?(APP). Defects in glycosylation of APP, tau and other proteins have been reported in AD
4	O-linked glycosylation	Alzheimer's disease		P		24144743
4	[Reference]: XXD can regulate the expression of OGT and O-GlcNAc glycosidase to enhance O-GlcNAc glycosylation of tau proteins in the hippocampus of SAD rats
5	Glycosylation	Sporadic Alzheimer disease		P		24024334
5	[Reference]: XXD can significantly improve O-GlcNAc glycosylation level of tau proteins in the hippocampus of SAD rats, which maybe inhibit hyperphosphorylation of tau proteins on key sites and its toxicity, and prevent the pathological process of SAD.
6	Serine Phosphorylation	Diabetes mellitus		U		19659459
6	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.
7	Phosphorylation	Alzheimer's disease		U		24411482; 24319659; 24497730
7	[Reference]: Hyperphosphorylation and aggregation of TAU cause neurofibrillary pathologies, including tangles and neuropil threads that are often seen in brains of patients with Alzheimer?? disease (AD)
8	Phosphorylation	Type 2 diabetic		U		24411482
8	[Reference]: Notably, patients with T2D have increased levels of hyperphosphorylated tau in their brains
9	Serine Phosphorylation	Alzheimer's disease		U	S	23726868
9	[Reference]: On the other hand, in 3xTg-AD mice treated with spa-water (12 ml/kg i.p.) the phosphorylation/expression level of the amyloid/tau cascade proteins was impressively decreased, as compared with that of saline-treated 3xTg-AD mice
10	Dephosphorylation	Alzheimer's disease		U		3950283; 24618580
10	[Reference]: tau was enriched in the neurites and sparse in the soma of SH-SY5Y cells induced to differentiate by retinoic acid (RA). Treatment with RA also increased total tau?protein?levels but decreased expression of tau phosphorylated at Ser262 as determined by Western blot. Both effects were further enhanced by subsequent BDNF treatment
11	Lysine Methylation	Alzheimer's disease		P	K24	24869773
11	[Reference]: Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity
12	Threonine Phosphorylation	Alzheimer's disease		P	T39	15517432
12	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
13	Lysine Methylation	Alzheimer's disease		P	K44	2203387; 24869773
13	[Reference]: Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity
14	Serine Phosphorylation	Alzheimer's disease		P	S46	15517432
14	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
15	Serine Phosphorylation	Progressive supranuclear palsy		U	S46	18315566
15	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
16	Threonine Phosphorylation	Alzheimer's disease		A	T50	15517432
16	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
17	Lysine Methylation	Alzheimer's disease		P	K67	24869773
17	[Reference]: Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity
18	Threonine Phosphorylation	Alzheimer's disease		P	T69	15517432
18	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
19	Threonine Phosphorylation	Alzheimer's disease		P	T123	15517432
19	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
20	Serine Phosphorylation	Alzheimer's disease		A	S131	15517432
20	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
21	Threonine Phosphorylation	Alzheimer's disease		A	T135	15517432
21	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
22	Serine Phosphorylation	Alzheimer's disease		P	S137	15517432
22	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
23	Threonine Phosphorylation	Alzheimer's disease		P	T153	15517432
23	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
24	Lysine Methylation	Alzheimer's disease		P	K163	22033876
24	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
25	Lysine Methylation	Alzheimer's disease		P	K174	22033876
25	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
26	Threonine Phosphorylation	Alzheimer's disease		P	T175	15517432
26	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
27	Lysine Methylation	Alzheimer's disease		P	K180	22033876
27	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
28	Threonine Phosphorylation	Alzheimer's disease		P	T181	15517432; 23439248
28	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
29	Threonine Phosphorylation	Corticobasal syndrome		U	T181	20836136
29	[Reference]: Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome
30	Serine Phosphorylation	Alzheimer's disease		A	S184	15517432
30	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
31	Lysine Methylation	Alzheimer's disease		P	K190	24869773
31	[Reference]: Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity
32	Serine Phosphorylation	Alzheimer's disease		A	S195	15517432
32	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
33	Serine Phosphorylation	Alzheimer's disease		P	S198	15517432
33	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
34	Serine Phosphorylation	Alzheimer's disease		P	S199	15517432
34	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
35	Serine Phosphorylation	Alzheimer's disease		P	S202	15517432
35	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
36	Threonine Phosphorylation	Alzheimer's disease		P	T205	15517432
36	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
37	Serine Phosphorylation	Alzheimer's disease		P	S208	15517432
37	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
38	Serine Phosphorylation	Alzheimer's disease		P	S210	15517432
38	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
39	Threonine Phosphorylation	Alzheimer's disease		P	T212	15517432
39	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
40	Serine Phosphorylation	Alzheimer's disease		P	S214	15517432
40	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
41	Threonine Phosphorylation	Alzheimer's disease		P	T217	15517432
41	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
42	Threonine Phosphorylation	Alzheimer's disease		P	T231	24660612; 15517432; 23262393
42	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
43	Serine Phosphorylation	Alzheimer's disease		P	S235	15517432
43	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
44	Serine Phosphorylation	Alzheimer's disease		P	S237	15517432
44	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
45	Serine Phosphorylation	Alzheimer's disease		P	S238	15517432
45	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
46	Serine Phosphorylation	Alzheimer's disease		P	S241	15517432
46	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
47	Lysine Methylation	Alzheimer's disease		P	K254	22033876
47	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
48	Serine Phosphorylation	Alzheimer's disease	tumor tissue	U	S262	23001711
48	[Reference]: Enhanced phosphorylation of tau on Ser(262) is detected early in the course of the disease and may have a role in the formation of tangles
49	Lysine Methylation	Alzheimer's disease		P	K267	22033876
49	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
50	Serine Phosphorylation	Alzheimer's disease		P	S285	15517432
50	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
51	Lysine Methylation	Alzheimer's disease		P	K290	22033876
51	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
52	Serine Phosphorylation	Alzheimer's disease		P	S305	15517432
52	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
53	Serine Phosphorylation	Alzheimer's disease		P	S324	15517432
53	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
54	Serine Phosphorylation	Alzheimer's disease		P	S352	15517432
54	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
55	Serine Phosphorylation	Alzheimer's disease		P	S356	15517432
55	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
56	Threonine Phosphorylation	Alzheimer's disease		P	T373	15517432
56	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
57	Serine Phosphorylation	Alzheimer's disease		P	S396	15517432; 23262393
57	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.;High-dose iron treatment markedly increased the levels of tau phosphorylation at the sites of Thr205, Thr231 and Ser396, whereas highly induced tau phosphorylation was abolished by intranasal administration of DFO in APP/PS3 transgenic mice.
58	Serine Phosphorylation	Alzheimer's disease		P	S400	15517432
58	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
59	Threonine Phosphorylation	Alzheimer's disease		P	T403	15517432
59	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
60	Threonine Phosphorylation	Alzheimer's disease		P	T404	15517432
60	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
61	Serine Phosphorylation	Alzheimer's disease		A	S409	15517432
61	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies
62	Serine Phosphorylation	Alzheimer's disease		P	S412	15517432
62	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
63	Serine Phosphorylation	Alzheimer's disease		A	S413	15517432
63	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies
64	Serine Phosphorylation	Alzheimer's disease		P	S416	15517432
64	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
65	Threonine Phosphorylation	Progressive supranuclear palsy		U	T498	18315566
65	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
66	Threonine Phosphorylation	Frontotemporal lobar degeneration		U	T498	15136685
66	[Reference]: Increased in early-onset Alzheimer disease patients, as compared to frontotemporal lobar degeneration or normal control patients. AD was highest, and FTLD higher than normal controls.
67	Threonine Phosphorylation	Alzheimer's disease		U	T498	19659459; 17314187; 21828286; 15136685; 12614922; 9832145
67	[Reference]: Increased in early-onset Alzheimer disease patients, as compared to frontotemporal lobar degeneration or normal control patients. AD was highest, and FTLD higher than normal controls.;;;;;
68	Tyrosine Phosphorylation	Alzheimer's disease		U	Y514	9832145
68	[Reference]: New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.
69	Serine Phosphorylation	Alzheimer's disease		U	S515	15126504; 9832145
69	[Reference]: Remarkably knock-down of WOX1 expression by small interfering RNA in neuroblastoma SK-N-SH cells spontaneously induced Tau phosphorylation at Thr212/Thr231 and Ser515/Ser516, enhanced phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) and ERK, and enhanced NFT formation.
70	Serine Phosphorylation	Diabetes mellitus		U	S519	19659459
70	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.
71	Serine Phosphorylation	Alzheimer's disease		U	S527	9832145
71	[Reference]: New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.
72	Threonine Phosphorylation	Alzheimer's disease		U	T529	15126504; 21828286; 19451179; 19821112; 9832145; 18725412
72	[Reference]: Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer's disease.
73	Threonine Phosphorylation	Progressive supranuclear palsy		U	T548	18315566
73	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
74	Threonine Phosphorylation	Alzheimer's disease		U	T548	22278060; 12766916; 15126504; 21828286; 19821112; 9832145; 15883264; 15324364
74	[Reference]: potential biomarker for Alzheimer's as distinct from other dementias. Phosphorylation occurs at early and later stages of AD.;AD diagnostic tool
75	Serine Phosphorylation	Diabetes mellitus		U	S579	19659459
75	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.
76	Serine Phosphorylation	Alzheimer's disease		U	S713	19659459; 11943712; 19451179; 21828286; 9832145; 8318230; 18725412; 20110615; 11034902
76	[Reference]: ;S396 and S304 are hyperphosphorylated in the CSF of AD patients as compared with normal controls. useful diagnostic marker of AD;;;;Antibodies to phosphorylated S396/404 stain brain sections early in the disease. ;;;
77	Serine Phosphorylation	Diabetes mellitus		U	S713	19659459
77	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.
78	Serine Phosphorylation	Progressive supranuclear palsy		U	S713	18315566
78	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
79	Serine Phosphorylation	Progressive supranuclear palsy		U	S717	18315566
79	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
80	Threonine Phosphorylation	Alzheimer's disease		U	T720	9832145; 21828286
80	[Reference]: New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.
81	Serine Phosphorylation	Diabetes mellitus		U	S739	19659459
81	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.

※ Disease Cross-ref Annotation

Database	Annotation
CTD (Curated) (count: 19) (view all)	MESH:D000544 ; Alzheimer Disease MESH:D003072 ; Cognition Disorders MESH:D003704 ; Dementia MESH:D004195 ; Disease Models, Animal MESH:D057180 ; Frontotemporal Dementia MESH:D007859 ; Learning Disorders MESH:D008569 ; Memory Disorders MESH:D019636 ; Neurodegenerative Diseases MESH:D010300 ; Parkinson Disease OMIM:168600 ; PARKINSON DISEASE, LATE-ONSET MESH:D020734 ; Parkinsonian Disorders MESH:D020774 ; Pick Disease of the Brain MESH:C537240 ; Progressive supranuclear palsy atypical MESH:D011595 ; Psychomotor Agitation MESH:D012131 ; Respiratory Insufficiency MESH:D013163 ; Splenomegaly MESH:D013494 ; Supranuclear Palsy, Progressive MESH:D024801 ; Tauopathies MESH:D015431 ; Weight Loss
DisGeNet (Curated) (count: 99) (view all)	C0001807; Aggressive behavior C0002018; Alexia C0002395; Alzheimer's Disease C0002736; Amyotrophic Lateral Sclerosis C0003467; Anxiety C0003635; Apraxias C0005586; Bipolar Disorder C0009241; Cognition Disorders C0011168; Deglutition Disorders C0011581; Depressive disorder C0012569; Diplopia C0013362; Dysarthria C0013528; Echolalia C0017639; Gliosis C0020505; Hyperphagia C0023015; Language Disorders C0023186; Learning Disorders C0025261; Memory Disorders C0026837; Muscle Rigidity C0026884; Mutism C0030567; Parkinson Disease C0035229; Respiratory Insufficiency C0038002; Splenomegaly C0038271; Stereotyped Behavior C0038273; Stereotypic Movement Disorder C0038868; Progressive supranuclear palsy C0040822; Tremor C0085400; Neurofibrillary degeneration (morphologic abnormality) C0085623; Akinesia C0085632; Apathy C0085636; Photophobia C0232461; Increased appetite (finding) C0233565; Bradykinesia C0233794; Memory impairment C0234132; Pyramidal sign C0234144; Dysgraphia C0236642; Pick Disease of the Brain C0240735; Personality change C0242422; Parkinsonian Disorders C0333454; Granulovacuolar degeneration C0338451; Frontotemporal dementia C0338455; Dementia of frontal lobe type C0338462; Semantic Dementia C0344232; Blurred vision C0424290; Compulsive hoarding C0424296; Social disinhibition C0424304; Inappropriate laughter C0424323; Physical aggression C0474420; Inappropriate sexual behavior C0476254; Dyslexia C0497327; Dementia C0524851; Neurodegenerative Disorders C0542223; Loss of speech C0542476; Forgetful C0575158; Kyphoscoliosis deformity of spine C0751295; Memory Loss C0751401; Ophthalmoparesis C0751706; Primary Progressive Nonfluent Aphasia C0948163; Leukoaraiosis C0949664; Tauopathies C0973461; Dysphasia C1142448; Apraxia of eyelid C1262477; Weight decreased C1411876; Developmental arithmetic disorder C1457883; Aggressive reaction C1720037; Supranuclear gaze palsy C1836149; Axial dystonia C1836150; Gait imbalance C1836151; Frontolimbic dementia C1836940; Excess nuchal skin C1838319; Primitive reflexes (palmomental, snout, glabellar) C1838320; Hyperorality C1848207; Poor speech C1850077; Supranuclear Palsy, Progressive, 1, Atypical C1850496; Neuronal loss C1853237; Isolated cases C1853562; Adult onset C2675334; Restrictive behavior, interests, and activities C2700617; Irritation - emotion C3160718; PARKINSON DISEASE, LATE-ONSET C3887611; Restlessness C3887612; Psychomotor Agitation C3887667; Retrocollis C4011788; Behavioral variant of frontotemporal dementia C4020851; Cortical white matter abnormalities seen on MRI C4020859; Pyramidal tract disease C4020884; Anxiety disease C4020887; Photodysphoria C4021584; Frontotemporal cerebral atrophy C4021761; Morphological abnormality of the pyramidal tract C4021799; Restrictive behavior C4022798; Abnormal brain FDG positron emission tomography C4023470; EEG with continuous slow activity C4024936; Temporal cortical atrophy C4024956; Grammar-specific speech disorder C4072928; Spoken Word Recognition Deficit C4280380; Repeated speech C4280574; Problems speaking C4280576; Difficulty making arithmetical calculations
HGMD (count: 57) (view all)	CP057307; Dementia, assoc. with ?; Complex rearrangements CD013179; Frontotemporal dementia, with parkinsonism; Small deletions CD991787; Frontotemporal dementia; Small deletions CG066477; Angelman syndrome ?; Gross deletions CG068243; Mental retardation ; Gross deletions CG091641; Frontotemporal dementia; Gross deletions CG064791; Mental retardation; Gross deletions CM020737; Frontotemporal dementia; Missense/nonsense CM022222; Supranuclear palsy, progressive; Missense/nonsense CM044902; Frontotemporal dementia ?; Missense/nonsense CM003942; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM014799; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM030233; Frontotemporal dementia; Missense/nonsense CM981233; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM061107; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM981234; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM014584; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM076274; Frontotemporal dementia; Missense/nonsense CM993836; Frontotemporal dementia/corticobasal degeneration; Missense/nonsense CM981235; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM053303; Supranuclear palsy, progressive; Missense/nonsense CM992927; Frontotemporal dementia; Missense/nonsense CM032951; Frontotemporal dementia; Missense/nonsense CM043764; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM020738; Frontotemporal dementia; Missense/nonsense CM055411; Frontotemporal dementia; Missense/nonsense CM074932; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM042738; Frontotemporal dementia; Missense/nonsense CM981236; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM003156; Frontotemporal dementia; Missense/nonsense CM034824; Respiratory failure; Missense/nonsense CM076275; Aphasia, progressive nonfluent; Missense/nonsense CM013000; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM004888; Frontotemporal dementia; Missense/nonsense CM994385; Frontotemporal dementia; Missense/nonsense CM981237; Frontotemporal dementia, with parkinsonism; Missense/nonsense CM055410; Parkinson disease; Missense/nonsense CM043765; Frontotemporal dementia; Missense/nonsense CR994768; Supranuclear palsy, progressive, association with; Regulatory CR091295; Progressive supranuclear palsy, association with ?; Regulatory CS055594; Frontotemporal dementia; Splicing CS982261; Frontotemporal dementia, with parkinsonism; Splicing CS033125; Frontotemporal dementia; Splicing CS000864; Frontotemporal dementia; Splicing CS982262; Frontotemporal dementia, with parkinsonism; Splicing CS982263; Frontotemporal dementia, with parkinsonism; Splicing CS982264; Frontotemporal dementia, with parkinsonism; Splicing CS033126; Frontotemporal dementia; Splicing CS084750; Argyrophilic grain disease; Splicing CS994525; Frontotemporal dementia, with parkinsonism; Splicing CS003183; Frontotemporal dementia/corticobasal degeneration; Splicing CS004157; Supranuclear palsy, progressive; Splicing CS012211; Frontotemporal dementia, with parkinsonism; Splicing CS000463; Alzheimer disease, increased risk, association; Splicing CS034626; Frontotemporal dementia, association with; Splicing CS065589; Frontotemporal dementia; Splicing CS991445; Frontotemporal dementia; Splicing
GWASdb (count: 366) (view all)	rs11575895; Primary biliary cirrhosis; primary biliary cirrhosis rs62056779; Primary biliary cirrhosis; primary biliary cirrhosis rs11575896; Primary biliary cirrhosis; primary biliary cirrhosis rs74457229; Primary biliary cirrhosis; primary biliary cirrhosis rs74548327; Primary biliary cirrhosis; primary biliary cirrhosis rs111972148; Primary biliary cirrhosis; primary biliary cirrhosis rs76324150; Primary biliary cirrhosis; primary biliary cirrhosis rs113347741; Primary biliary cirrhosis; primary biliary cirrhosis rs78720789; Primary biliary cirrhosis; primary biliary cirrhosis rs4792891; Parkinson's disease; Parkinson's disease rs62056780; Primary biliary cirrhosis; primary biliary cirrhosis rs62056782; Primary biliary cirrhosis; primary biliary cirrhosis rs113161176; Primary biliary cirrhosis; primary biliary cirrhosis rs80346216; Primary biliary cirrhosis; primary biliary cirrhosis rs76632685; Primary biliary cirrhosis; primary biliary cirrhosis rs62056783; Primary biliary cirrhosis; primary biliary cirrhosis rs62056784; Primary biliary cirrhosis; primary biliary cirrhosis rs11079727; HDL cholesterol particle diameter; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease rs1864325; Multiple complex diseases; Null rs1864325; Parkinson's disease; Parkinson's disease rs1864325; Bone mineral density; bone resorption disease rs1864325; Male-pattern baldness; alopecia rs1864325; Primary biliary cirrhosis; primary biliary cirrhosis rs1864325; Red blood cell traits; hematopoietic system disease rs1864325; Bone mineral density (paediatric, lower limb); bone resorption disease rs1560310; Red blood cell traits; hematopoietic system disease rs2099151; Red blood cell traits; hematopoietic system disease rs2082068; Red blood cell traits; hematopoietic system disease rs1984937; Red blood cell traits; hematopoietic system disease rs17563965; Red blood cell traits; hematopoietic system disease rs17563986; Parkinson's disease; Parkinson's disease rs17563986; Red blood cell traits; hematopoietic system disease rs17563986; Interstitial lung disease; interstitial lung disease rs17564020; Red blood cell traits; hematopoietic system disease rs17649518; Red blood cell traits; hematopoietic system disease rs17649553; Primary biliary cirrhosis; primary biliary cirrhosis rs17649553; Red blood cell traits; hematopoietic system disease rs17649571; Red blood cell traits; hematopoietic system disease rs17564153; Red blood cell traits; hematopoietic system disease rs17649641; Multiple complex diseases; Null rs17649641; Primary biliary cirrhosis; primary biliary cirrhosis rs17649641; Red blood cell traits; hematopoietic system disease rs17564223; Multiple complex diseases; Null rs17564223; Red blood cell traits; hematopoietic system disease rs17649700; Multiple complex diseases; Null rs17649700; Red blood cell traits; hematopoietic system disease rs1467969; Multiple complex diseases; Null rs1467969; Red blood cell traits; hematopoietic system disease rs1467970; Red blood cell traits; hematopoietic system disease rs767058; Primary biliary cirrhosis; primary biliary cirrhosis rs767058; Red blood cell traits; hematopoietic system disease rs767057; Parkinson's disease; Parkinson's disease rs767057; Primary biliary cirrhosis; primary biliary cirrhosis rs767057; Red blood cell traits; hematopoietic system disease rs767056; Red blood cell traits; hematopoietic system disease rs767059; Red blood cell traits; hematopoietic system disease rs4792894; Urinary metabolites; kidney disease rs8079501; Red blood cell traits; hematopoietic system disease rs8078495; Red blood cell traits; hematopoietic system disease rs17649866; Red blood cell traits; hematopoietic system disease rs17564493; Multiple complex diseases; Null rs17564493; Red blood cell traits; hematopoietic system disease rs17649918; Red blood cell traits; hematopoietic system disease rs17649954; Multiple complex diseases; Null rs17649954; Red blood cell traits; hematopoietic system disease rs17564619; Multiple complex diseases; Null rs17564619; Red blood cell traits; hematopoietic system disease rs17650063; Multiple complex diseases; Null rs17650063; Primary biliary cirrhosis; primary biliary cirrhosis rs17650063; Red blood cell traits; hematopoietic system disease rs16940742; Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption); hypertension rs17564780; Multiple complex diseases; Null rs17564780; Red blood cell traits; hematopoietic system disease rs17564829; Primary biliary cirrhosis; primary biliary cirrhosis rs8078967; Parkinson's disease; Parkinson's disease rs7501759; Red blood cell traits; hematopoietic system disease rs2316782; Red blood cell traits; hematopoietic system disease rs2316783; Red blood cell traits; hematopoietic system disease rs17564871; Red blood cell traits; hematopoietic system disease rs17564948; Red blood cell traits; hematopoietic system disease rs17564983; Parkinson's disease; Parkinson's disease rs17564983; Red blood cell traits; hematopoietic system disease rs17650335; Red blood cell traits; hematopoietic system disease rs17565025; Red blood cell traits; hematopoietic system disease rs17650381; Multiple complex diseases; Null rs17650381; Red blood cell traits; hematopoietic system disease rs17650417; Red blood cell traits; hematopoietic system disease rs12150111; Multiple complex diseases; Null rs12150111; Primary biliary cirrhosis; primary biliary cirrhosis rs12150111; Red blood cell traits; hematopoietic system disease rs12150460; Red blood cell traits; hematopoietic system disease rs12150195; Red blood cell traits; hematopoietic system disease rs12150229; Red blood cell traits; hematopoietic system disease rs12150230; Red blood cell traits; hematopoietic system disease rs12150576; Red blood cell traits; hematopoietic system disease rs12150235; Red blood cell traits; hematopoietic system disease rs12150242; Red blood cell traits; hematopoietic system disease rs12150104; Red blood cell traits; hematopoietic system disease rs242557; Progressive supranuclear palsy; progressive supranuclear palsy rs2316784; Red blood cell traits; hematopoietic system disease rs4327091; Brain structure; Alzheimer's disease rs4327091; Red blood cell traits; hematopoietic system disease rs62062784; Primary biliary cirrhosis; primary biliary cirrhosis rs62062785; Primary biliary cirrhosis; primary biliary cirrhosis rs242559; Multiple complex diseases; Null rs242559; Brain structure; Alzheimer's disease rs242559; Male-pattern baldness; alopecia rs242559; 2-hour glucose tolerance test; type 2 diabetes mellitus rs242559; Red blood cell traits; hematopoietic system disease rs62062793; Primary biliary cirrhosis; primary biliary cirrhosis rs62062794; Primary biliary cirrhosis; primary biliary cirrhosis rs78556223; Primary biliary cirrhosis; primary biliary cirrhosis rs77266933; Primary biliary cirrhosis; primary biliary cirrhosis rs74531363; Primary biliary cirrhosis; primary biliary cirrhosis rs242561; Primary biliary cirrhosis; primary biliary cirrhosis rs62062795; Primary biliary cirrhosis; primary biliary cirrhosis rs62062796; Primary biliary cirrhosis; primary biliary cirrhosis rs62062797; Primary biliary cirrhosis; primary biliary cirrhosis rs62062798; Primary biliary cirrhosis; primary biliary cirrhosis rs17650579; Red blood cell traits; hematopoietic system disease rs17650597; Red blood cell traits; hematopoietic system disease rs17650633; Red blood cell traits; hematopoietic system disease rs17650651; Red blood cell traits; hematopoietic system disease rs17571718; Multiple complex diseases; Null rs17571718; Brain structure; Alzheimer's disease rs17571718; Male-pattern baldness; alopecia rs17571718; Red blood cell traits; hematopoietic system disease rs17571739; Multiple complex diseases; Null rs17571739; Brain structure; Alzheimer's disease rs17571739; Male-pattern baldness; alopecia rs17571739; Primary biliary cirrhosis; primary biliary cirrhosis rs17571739; Red blood cell traits; hematopoietic system disease rs17571781; Male-pattern baldness; alopecia rs17571781; Red blood cell traits; hematopoietic system disease rs17571809; Male-pattern baldness; alopecia rs17571809; Primary biliary cirrhosis; primary biliary cirrhosis rs17571809; Red blood cell traits; hematopoietic system disease rs17650771; Male-pattern baldness; alopecia rs17650771; Red blood cell traits; hematopoietic system disease rs17571857; Brain structure; Alzheimer's disease rs17571857; Male-pattern baldness; alopecia rs17571857; Red blood cell traits; hematopoietic system disease rs17650818; Male-pattern baldness; alopecia rs17650818; Red blood cell traits; hematopoietic system disease rs17650842; Male-pattern baldness; alopecia rs17650842; Red blood cell traits; hematopoietic system disease rs17650860; Brain structure; Alzheimer's disease rs17650860; Male-pattern baldness; alopecia rs17650860; Red blood cell traits; hematopoietic system disease rs17650872; Multiple complex diseases; Null rs17650872; Brain structure; Alzheimer's disease rs17650872; Male-pattern baldness; alopecia rs17650872; Red blood cell traits; hematopoietic system disease rs17650901; Parkinson's disease; Parkinson's disease rs17650901; Male-pattern baldness; alopecia rs17650901; Red blood cell traits; hematopoietic system disease rs17650973; Male-pattern baldness; alopecia rs17650973; Red blood cell traits; hematopoietic system disease rs17650991; Obesity (extreme); obesity rs17650991; Male-pattern baldness; alopecia rs17650991; Red blood cell traits; hematopoietic system disease rs17572147; Male-pattern baldness; alopecia rs17572147; Red blood cell traits; hematopoietic system disease rs17572169; Multiple complex diseases; Null rs17572169; Brain structure; Alzheimer's disease rs17572169; Male-pattern baldness; alopecia rs17572169; Primary biliary cirrhosis; primary biliary cirrhosis rs17572169; Red blood cell traits; hematopoietic system disease rs75242405; Primary biliary cirrhosis; primary biliary cirrhosis rs17651093; Male-pattern baldness; alopecia rs17651093; Red blood cell traits; hematopoietic system disease rs17572248; Male-pattern baldness; alopecia rs17572248; Red blood cell traits; hematopoietic system disease rs17651134; Male-pattern baldness; alopecia rs17651134; Red blood cell traits; hematopoietic system disease rs1800547; Parkinson's disease; Parkinson's disease rs1800547; Brain structure; Alzheimer's disease rs1800547; Male-pattern baldness; alopecia rs1800547; Red blood cell traits; hematopoietic system disease rs17651213; Multiple complex diseases; Null rs17651213; Brain structure; Alzheimer's disease rs17651213; Male-pattern baldness; alopecia rs17651213; Primary biliary cirrhosis; primary biliary cirrhosis rs17651213; Red blood cell traits; hematopoietic system disease rs17572361; Multiple complex diseases; Null rs17572361; Brain structure; Alzheimer's disease rs17572361; Male-pattern baldness; alopecia rs17572361; Primary biliary cirrhosis; primary biliary cirrhosis rs17572361; Red blood cell traits; hematopoietic system disease rs17651243; Male-pattern baldness; alopecia rs17651243; Red blood cell traits; hematopoietic system disease rs78104015; Primary biliary cirrhosis; primary biliary cirrhosis rs62063777; Primary biliary cirrhosis; primary biliary cirrhosis rs2217394; Male-pattern baldness; alopecia rs2217394; Red blood cell traits; hematopoietic system disease rs17651285; Male-pattern baldness; alopecia rs17651285; Red blood cell traits; hematopoietic system disease rs17572467; Male-pattern baldness; alopecia rs17572467; Red blood cell traits; hematopoietic system disease rs17572495; Male-pattern baldness; alopecia rs17572495; Red blood cell traits; hematopoietic system disease rs754593; Parkinson's disease; Parkinson's disease rs754593; Red blood cell traits; hematopoietic system disease rs754512; Male-pattern baldness; alopecia rs754512; Red blood cell traits; hematopoietic system disease rs1981997; Parkinson's disease; Parkinson's disease rs1981997; Brain structure; Alzheimer's disease rs1981997; Red blood cell traits; hematopoietic system disease rs1981997; Interstitial lung disease; interstitial lung disease rs1981998; Male-pattern baldness; alopecia rs1981998; Red blood cell traits; hematopoietic system disease rs17572613; Male-pattern baldness; alopecia rs17572613; Red blood cell traits; hematopoietic system disease rs17572627; Male-pattern baldness; alopecia rs17572627; Red blood cell traits; hematopoietic system disease rs17651483; Male-pattern baldness; alopecia rs17651483; Red blood cell traits; hematopoietic system disease rs63750417; Primary biliary cirrhosis; primary biliary cirrhosis rs62063786; Primary biliary cirrhosis; primary biliary cirrhosis rs62063787; Primary biliary cirrhosis; primary biliary cirrhosis rs17651549; Parkinson's disease; Parkinson's disease rs17651549; Brain structure; Alzheimer's disease rs17651549; Male-pattern baldness; alopecia rs17651549; Primary biliary cirrhosis; primary biliary cirrhosis rs17651549; Red blood cell traits; hematopoietic system disease rs554819069; Primary biliary cirrhosis; primary biliary cirrhosis rs530157802; Primary biliary cirrhosis; primary biliary cirrhosis rs1529534; Male-pattern baldness; alopecia rs1529534; Red blood cell traits; hematopoietic system disease rs541986174; Male-pattern baldness; alopecia rs541986174; Red blood cell traits; hematopoietic system disease rs2435211; Type 2 diabetes; type 2 diabetes mellitus rs2435211; Brain structure; Alzheimer's disease rs17572795; Male-pattern baldness; alopecia rs17572795; Red blood cell traits; hematopoietic system disease rs531217003; Male-pattern baldness; alopecia rs531217003; Red blood cell traits; hematopoietic system disease rs17572823; Male-pattern baldness; alopecia rs17572823; Red blood cell traits; hematopoietic system disease rs571131167; Male-pattern baldness; alopecia rs571131167; Red blood cell traits; hematopoietic system disease rs531963580; Primary biliary cirrhosis; primary biliary cirrhosis rs9901937; Primary biliary cirrhosis; primary biliary cirrhosis rs547435395; Multiple complex diseases; Null rs547435395; Brain structure; Alzheimer's disease rs547435395; Male-pattern baldness; alopecia rs547435395; Red blood cell traits; hematopoietic system disease rs565744479; Primary biliary cirrhosis; primary biliary cirrhosis rs17572893; Multiple complex diseases; Null rs17572893; Brain structure; Alzheimer's disease rs17572893; Male-pattern baldness; alopecia rs17572893; Red blood cell traits; hematopoietic system disease rs537342897; Multiple complex diseases; Null rs537342897; Brain structure; Alzheimer's disease rs537342897; Male-pattern baldness; alopecia rs537342897; Red blood cell traits; hematopoietic system disease rs552965964; Male-pattern baldness; alopecia rs552965964; Red blood cell traits; hematopoietic system disease rs10445371; Male-pattern baldness; alopecia rs10445371; Primary biliary cirrhosis; primary biliary cirrhosis rs10445371; Red blood cell traits; hematopoietic system disease rs919461; Primary biliary cirrhosis; primary biliary cirrhosis rs919461; Red blood cell traits; hematopoietic system disease rs919462; Primary biliary cirrhosis; primary biliary cirrhosis rs919464; Primary biliary cirrhosis; primary biliary cirrhosis rs919464; Red blood cell traits; hematopoietic system disease rs17651700; Red blood cell traits; hematopoietic system disease rs10445337; Parkinson's disease; Parkinson's disease rs10445337; Red blood cell traits; hematopoietic system disease rs10445337; Primary biliary cirrhosis; primary biliary cirrhosis rs17651754; Red blood cell traits; hematopoietic system disease rs10445338; Parkinson's disease; Parkinson's disease rs10445338; Red blood cell traits; hematopoietic system disease rs62063796; Primary biliary cirrhosis; primary biliary cirrhosis rs62063797; Primary biliary cirrhosis; primary biliary cirrhosis rs11656151; Alzheimer's disease (late onset); Alzheimer's disease rs1052551; Parkinson's disease; Parkinson's disease rs1052551; Brain structure; Alzheimer's disease rs17573175; Multiple complex diseases; Null rs17573175; Parkinson's disease; Parkinson's disease rs17573175; Brain structure; Alzheimer's disease rs17573175; Red blood cell traits; hematopoietic system disease rs2435200; Parkinson's disease; Parkinson's disease rs2435200; Red blood cell traits; hematopoietic system disease rs17652036; Red blood cell traits; hematopoietic system disease rs17652066; Primary biliary cirrhosis; primary biliary cirrhosis rs1052553; Parkinson's disease; Parkinson's disease rs1052553; Brain structure; Alzheimer's disease rs1052553; Red blood cell traits; hematopoietic system disease rs17652121; Parkinson's disease; Parkinson's disease rs17652121; Primary biliary cirrhosis; primary biliary cirrhosis rs17652121; Red blood cell traits; hematopoietic system disease rs62063851; Primary biliary cirrhosis; primary biliary cirrhosis rs62063852; Primary biliary cirrhosis; primary biliary cirrhosis rs62063853; Primary biliary cirrhosis; primary biliary cirrhosis rs62063854; Primary biliary cirrhosis; primary biliary cirrhosis rs1078268; Multiple complex diseases; Null rs1078268; Parkinson's disease; Parkinson's disease rs1078268; Brain structure; Alzheimer's disease rs1078268; Primary biliary cirrhosis; primary biliary cirrhosis rs1078268; Red blood cell traits; hematopoietic system disease rs62064662; Primary biliary cirrhosis; primary biliary cirrhosis rs138957038; Primary biliary cirrhosis; primary biliary cirrhosis rs62064663; Primary biliary cirrhosis; primary biliary cirrhosis rs8070723; Multiple complex diseases; Null rs8070723; Parkinson's disease; Parkinson's disease rs8070723; Primary biliary cirrhosis; primary biliary cirrhosis rs8070723; Progressive supranuclear palsy; progressive supranuclear palsy rs8070723; Brain structure; Alzheimer's disease rs8070723; Red blood cell traits; hematopoietic system disease rs8070723; Interstitial lung disease; interstitial lung disease rs17573509; Parkinson's disease; Parkinson's disease rs17573593; Red blood cell traits; hematopoietic system disease rs17573607; Red blood cell traits; hematopoietic system disease rs17652337; Red blood cell traits; hematopoietic system disease rs1991556; Parkinson's disease; Parkinson's disease rs1991556; Red blood cell traits; hematopoietic system disease rs8067056; Parkinson's disease; Parkinson's disease rs8067056; Obesity (extreme); obesity rs8067056; Red blood cell traits; hematopoietic system disease rs17652449; Multiple complex diseases; Null rs17652449; Brain structure; Alzheimer's disease rs17652449; Primary biliary cirrhosis; primary biliary cirrhosis rs17652449; Red blood cell traits; hematopoietic system disease rs733966; Red blood cell traits; hematopoietic system disease rs75666751; Primary biliary cirrhosis; primary biliary cirrhosis rs551853349; Brain structure; Alzheimer's disease rs551853349; Red blood cell traits; hematopoietic system disease rs12150170; Red blood cell traits; hematopoietic system disease rs12150515; Red blood cell traits; hematopoietic system disease rs17573858; Red blood cell traits; hematopoietic system disease rs17652502; Multiple complex diseases; Null rs17652502; Brain structure; Alzheimer's disease rs17652502; Primary biliary cirrhosis; primary biliary cirrhosis rs17652502; Red blood cell traits; hematopoietic system disease rs9468; Alzheimer's disease (late onset); Alzheimer's disease rs9468; Parkinson's disease; Parkinson's disease rs9468; Red blood cell traits; hematopoietic system disease rs1052587; Parkinson's disease; Parkinson's disease rs1052587; Brain structure; Alzheimer's disease rs1052587; Primary biliary cirrhosis; primary biliary cirrhosis rs1052587; Red blood cell traits; hematopoietic system disease rs1052590; Primary biliary cirrhosis; primary biliary cirrhosis rs1052594; Primary biliary cirrhosis; primary biliary cirrhosis rs1052594; Red blood cell traits; hematopoietic system disease rs17574040; Parkinson's disease; Parkinson's disease rs17574040; Primary biliary cirrhosis; primary biliary cirrhosis rs17574040; Red blood cell traits; hematopoietic system disease rs16940799; Parkinson's disease; Parkinson's disease rs16940799; Primary biliary cirrhosis; primary biliary cirrhosis rs16940799; Red blood cell traits; hematopoietic system disease rs7687; Primary biliary cirrhosis; primary biliary cirrhosis rs7687; Red blood cell traits; hematopoietic system disease rs17652748; Primary biliary cirrhosis; primary biliary cirrhosis rs17652748; Red blood cell traits; hematopoietic system disease rs75010486; Primary biliary cirrhosis; primary biliary cirrhosis rs16940806; Primary biliary cirrhosis; primary biliary cirrhosis rs2158257; Parkinson's disease; Parkinson's disease rs2158257; Primary biliary cirrhosis; primary biliary cirrhosis rs2158257; Red blood cell traits; hematopoietic system disease rs17574228; Multiple complex diseases; Null rs17574228; Parkinson's disease; Parkinson's disease rs17574228; Primary biliary cirrhosis; primary biliary cirrhosis rs17574228; Red blood cell traits; hematopoietic system disease rs7521; Parkinson's disease; Parkinson's disease rs7521; Red blood cell traits; hematopoietic system disease

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 99) (view all)	101 HTEIPEGTTAEEAGI dbPAF 102 TEIPEGTTAEEAGIG dbPAF 111 EEAGIGDTPSLEDEA dbPAF 113 AGIGDTPSLEDEAAG dbPAF 123 DEAAGHVTQEPESGK dbPAF 17 VMEDHAGTYGLGDRK dbPAF 171 REATRQPSGTGPEDT dbPAF 173 ATRQPSGTGPEDTEG dbPAF 18 MEDHAGTYGLGDRKD dbPAF 214 GGKERPGSKEEVDED dbPAF 227 EDRDVDESSPQDSPP dbPAF 228 DRDVDESSPQDSPPS dbPAF 232 DESSPQDSPPSKASP dbPAF 235 SPQDSPPSKASPAQD dbPAF 238 DSPPSKASPAQDGRP dbPAF 29 DRKDQGGYTMHQDQE dbPAF 30 RKDQGGYTMHQDQEG dbPAF 355 EADLPEPSEKQPAAA dbPAF 369 APRGKPVSRVPQLKA dbPAF 382 KARMVSKSKDGTGSD dbPAF 386 VSKSKDGTGSDDKKA dbPAF 388 KSKDGTGSDDKKAKT dbPAF 39 HQDQEGDTDAGLKES dbPAF 396 DDKKAKTSTRSSAKT dbPAF 400 AKTSTRSSAKTLKNR dbPAF 403 STRSSAKTLKNRPCL dbPAF 411 LKNRPCLSPKHPTPG dbPAF 428 DPLIQPSSPAVCPEP dbPAF 437 AVCPEPPSSPKYVSS dbPAF 438 VCPEPPSSPKYVSSV dbPAF 449 VSSVTSRTGSSGAKE dbPAF 451 SVTSRTGSSGAKEMK dbPAF 46 TDAGLKESPLQTPTE dbPAF 466 LKGADGKTKIATPRG dbPAF 470 DGKTKIATPRGAAPP dbPAF 486 QKGQANATRIPAKTP dbPAF 492 ATRIPAKTPPAPKTP dbPAF 498 KTPPAPKTPPSSGEP dbPAF 50 LKESPLQTPTEDGSE dbPAF 501 PAPKTPPSSGEPPKS dbPAF 502 APKTPPSSGEPPKSG dbPAF 508 SSGEPPKSGDRSGYS dbPAF 512 PPKSGDRSGYSSPGS dbPAF 514 KSGDRSGYSSPGSPG dbPAF 515 SGDRSGYSSPGSPGT dbPAF 516 GDRSGYSSPGSPGTP dbPAF 519 SGYSSPGSPGTPGSR dbPAF 52 ESPLQTPTEDGSEEP dbPAF 522 SSPGSPGTPGSRSRT dbPAF 525 GSPGTPGSRSRTPSL dbPAF 527 PGTPGSRSRTPSLPT dbPAF 529 TPGSRSRTPSLPTPP dbPAF 531 GSRSRTPSLPTPPTR dbPAF 534 SRTPSLPTPPTREPK dbPAF 537 PSLPTPPTREPKKVA dbPAF 548 KKVAVVRTPPKSPSS dbPAF 552 VVRTPPKSPSSAKSR dbPAF 554 RTPPKSPSSAKSRLQ dbPAF 555 TPPKSPSSAKSRLQT dbPAF 558 KSPSSAKSRLQTAPV dbPAF 56 QTPTEDGSEEPGSET dbPAF 562 SAKSRLQTAPVPMPD dbPAF 575 PDLKNVKSKIGSTEN dbPAF 579 NVKSKIGSTENLKHQ dbPAF 580 VKSKIGSTENLKHQP dbPAF 602 INKKLDLSNVQSKCG dbPAF 606 LDLSNVQSKCGSKDN dbPAF 610 NVQSKCGSKDNIKHV dbPAF 622 KHVPGGGSVQIVYKP dbPAF 627 GGSVQIVYKPVDLSK dbPAF 633 VYKPVDLSKVTSKCG dbPAF 636 PVDLSKVTSKCGSLG dbPAF 637 VDLSKVTSKCGSLGN dbPAF 641 KVTSKCGSLGNIHHK dbPAF 658 GGQVEVKSEKLDFKD dbPAF 669 DFKDRVQSKIGSLDN dbPAF 673 RVQSKIGSLDNITHV dbPAF 678 IGSLDNITHVPGGGN dbPAF 68 SETSDAKSTPTAEDV dbPAF 69 ETSDAKSTPTAEDVT dbPAF 690 GGNKKIETHKLTFRE dbPAF 694 KIETHKLTFRENAKA dbPAF 703 RENAKAKTDHGAEIV dbPAF 71 SDAKSTPTAEDVTAP dbPAF 711 DHGAEIVYKSPVVSG dbPAF 713 GAEIVYKSPVVSGDT dbPAF 717 VYKSPVVSGDTSPRH dbPAF 720 SPVVSGDTSPRHLSN dbPAF 721 PVVSGDTSPRHLSNV dbPAF 726 DTSPRHLSNVSSTGS dbPAF 729 PRHLSNVSSTGSIDM dbPAF 730 RHLSNVSSTGSIDMV dbPAF 731 HLSNVSSTGSIDMVD dbPAF 733 SNVSSTGSIDMVDSP dbPAF 739 GSIDMVDSPQLATLA dbPAF 744 VDSPQLATLADEVSA dbPAF 750 ATLADEVSASLAKQG dbPAF 752 LADEVSASLAKQGL* dbPAF 95 QAAAQPHTEIPEGTT dbPAF
Acetylation (count: 26) (view all)	467 KGADGKTKIATPRGA PLMD 480 GAAPPGQKGQANATR PLMD 491 NATRIPAKTPPAPKT PLMD 497 AKTPPAPKTPPSSGE PLMD 507 PSSGEPPKSGDRSGY PLMD 551 AVVRTPPKSPSSAKS PLMD 557 PKSPSSAKSRLQTAP PLMD 571 PVPMPDLKNVKSKIG PLMD 574 MPDLKNVKSKIGSTE PLMD 576 DLKNVKSKIGSTENL PLMD 584 IGSTENLKHQPGGGK PLMD 591 KHQPGGGKVQIINKK PLMD 597 GKVQIINKKLDLSNV PLMD 598 KVQIINKKLDLSNVQ PLMD 607 DLSNVQSKCGSKDNI PLMD 615 CGSKDNIKHVPGGGS PLMD 628 GSVQIVYKPVDLSKV PLMD 634 YKPVDLSKVTSKCGS PLMD 638 DLSKVTSKCGSLGNI PLMD 648 SLGNIHHKPGGGQVE PLMD 670 FKDRVQSKIGSLDNI PLMD 686 HVPGGGNKKIETHKL PLMD 687 VPGGGNKKIETHKLT PLMD 700 LTFRENAKAKTDHGA PLMD 702 FRENAKAKTDHGAEI PLMD 712 HGAEIVYKSPVVSGD PLMD
Ubiquitination (count: 6)	391 DGTGSDDKKAKTSTR PLMD 497 AKTPPAPKTPPSSGE PLMD 557 PKSPSSAKSRLQTAP PLMD 571 PVPMPDLKNVKSKIG PLMD 628 GSVQIVYKPVDLSKV PLMD 670 FKDRVQSKIGSLDNI PLMD
Sumoylation (count: 1)	657 GGGQVEVKSEKLDFK PLMD
Glycation (count: 13) (view all)	383 ARMVSKSKDGTGSDD PLMD 467 KGADGKTKIATPRGA PLMD 480 GAAPPGQKGQANATR PLMD 491 NATRIPAKTPPAPKT PLMD 542 PPTREPKKVAVVRTP PLMD 551 AVVRTPPKSPSSAKS PLMD 576 DLKNVKSKIGSTENL PLMD 597 GKVQIINKKLDLSNV PLMD 598 KVQIINKKLDLSNVQ PLMD 664 KSEKLDFKDRVQSKI PLMD 670 FKDRVQSKIGSLDNI PLMD 686 HVPGGGNKKIETHKL PLMD 87 VDEGAPGKQAAAQPH PLMD
Methylation (count: 1)	611 VQSKCGSKDNIKHVP PLMD

※ Protein-Protein Interaction

Network

Interaction

Source

H0YG33	P10636	MINT
O15294	P10636	HPRD
O95793	P10636	IntAct
P05067	P10636	IntAct
P06241	P10636	MINT
P06493	P10636	HPRD
P10636	P10636	IntAct
P10636	P12931	MINT
P10636	P23443	MINT;HPRD
P10636	P30153	MINT
P10636	P31749	DIP;MINT
P10636	P31946	MINT
P10636	P37840	MINT;HPRD
P10636	P43004	MINT
P10636	P48730	MINT
P10636	P49768	HPRD
P10636	P49840	IntAct
P10636	P49841	MINT
P10636	P62158	HPRD
P10636	P62988	DIP
P10636	P63104	MINT
P10636	P63151	MINT
P10636	P67775	HPRD
P10636	Q00535	MINT
P10636	Q02790	DIP
P10636	Q05655	HPRD
P10636	Q13526	HPRD
P10636	Q14203	MINT
P10636	Q15418	MINT
P10636	Q96RG2	MINT
P10636	Q9NY61	MINT
P10636	Q9UNE7	DIP; IntAct;HPRD

PTMD Annotation Information

※ Protein Information

Functional Description

Fasta Sequence

※ PTM-Disease Association

※ Disease Cross-ref Annotation

※ PTM Sites

※ Protein-Protein Interaction